KYG0330A1013
KYG0330A1013
ALPHAMAB-B
Loading chart...
Financials
Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
| Breakdown | 2025 | 2024 | Change % |
|---|---|---|---|
| Total Revenue | 566.235.000 | 640.083.000 | 11.5% |
| Cost of Revenue | 63.546.000 | 60.316.000 | 5.4% |
| Gross Profit | 502.689.000 | 579.767.000 | 13.3% |
| 638.461.000 | 465.991.000 | 37.0% | |
| Operating Income | -135.772.000 | 113.776.000 | 219.3% |
| Pretax Income | -113.939.000 | 166.342.000 | 168.5% |
| Net Income Common Stockholders | -113.939.000 | 166.342.000 | 168.5% |
| -- | -- | -- | |
| -- | -- | -- |